



**KDIGO - Controversies Conference**  
**Chronic Kidney Disease as a Global Public Health  
Problem: Approaches and Initiatives**

**12-14 October, 2006**

**Renaissance Amsterdam, Amsterdam**


## Goals and Objectives

- Simple message
- Conceptual model and definition
- Prevalence
- Testing
- Classification
- Risk factors
- Relationship with other chronic diseases
- Rationale for public health policy


# CKD is a Public Health Problem

- CKD is common
- CKD is harmful
- We have treatment

# Conceptual Model for CKD



# Conceptual Model for AKI



AKIN Vancouver Conference 2006

# NKF-K/DOQI Definition of CKD

## KDIGO Modifications (Amsterdam 2004)

Structural or functional abnormalities of the kidneys for  $\geq 3$  months, as manifested by either:

1. **Kidney damage**, with or without decreased GFR, as defined by
  - pathologic abnormalities
  - **markers of kidney damage**
    - urinary abnormalities (**proteinuria**)
    - blood abnormalities (renal tubular syndromes)
    - imaging abnormalities
  - **kidney transplantation**
2. **GFR  $< 60$  ml/min/1.73 m<sup>2</sup>**, with or without kidney damage

An International Symposium, New York, May 16-18, 2004

# Role of Albuminuria in Health and Disease: Predicting Targets and Outcomes of Therapy

Guest Editors: De Zeeuw D; Bakris G; Pfeffer M

*Kidney International 2004: 66 (Supplement 92): S1-S127*

---

## **Where we are today:**

- Albuminuria is useful for detection, evaluation and management of CKD
- Spot urine albumin-to-creatinine ratio is easier to measure and correlates with timed excretion rate
- Ratio >30 mg/g is a maker of CKD
- Lower level is a risk factor for CVD

## **Next steps:**

- Urine albumin standardization
- Variation by sex, race, ethnicity and age
- Hypothesized relationship to generalized endothelial dysfunction
- Hypothesized surrogate marker for CKD progression

# Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate

Lesley A. Stevens, M.D., Josef Coresh, M.D., Ph.D., Tom Greene, Ph.D.,  
and Andrew S. Levey, M.D.

N Engl J Med 2006;354:2473-83

---

## **Where we are today:**

- eGFR is useful for detection, evaluation and management of CKD
- eGFR is more accurate than serum creatinine alone
- eGFR is less accurate at higher vs. lower levels
- eGFR reporting (numeric value only for eGFR <60)

## **Next steps to improve performance (especially at higher GFR):**

- Creatinine standardization
- Race/ethnicity terms
- New equations
  - new filtration markers
    - (cystatin C)
  - additional variables
  - new derivations

# Performance of MDRD Study Equation Using Calibrated and Non-Calibrated Creatinine

Study	N	mGFR	Non-Calibrated Creatinine		Calibrated Creatinine	
			% $\Delta$	P30	% $\Delta$	P30
MDRD Study	1085	40	-0.1	90	0.1	90
AASK	1205	57	7.7	85	2.1	86
DCCT	787	124	<b>14.9</b>	<b>81</b>	<b>10.1</b>	<b>85</b>
DRDS	126	115	13.5	76	-0.8	79
CSG	266	78	15.6	75	14.6	75
CRIC	446	50	8.0	82	8.7	81
CCF CKD	695	34	2.5	71	0.6	71
CCF Donors	301	106	<b>8.4</b>	<b>86</b>	<b>14.4</b>	<b>84</b>
Mayo CKD	221	48	8.0	76	0.4	76
Mayo Donors	372	102	<b>28.9</b>	<b>54</b>	<b>13.5</b>	<b>87</b>
<b>Pooled</b>	<b>5504</b>	<b>68</b>	<b>9.0</b>	<b>80</b>	<b>5.8</b>	<b>83</b>



Variable	Group	eGFR <60			eGFR ≥60		
		N	%Δ	P30	N	%Δ	P30
Age	<40	596	2.2	83	1468	9.9	83
	40-65	1701	4.6	83	1036	6.8	85
	>65	590	-1.3	82	113	-0.4	87
Female	Y	1218	3.6	82	1179	10.9	82
	N	1669	2.4	83	1438	6.6	86
Black	Y	1090	3.4	83	659	-0.3	87
	N	1797	2.5	82	1958	11.0	83
Diabetes	Y	507	5.9	74	1073	9.6	83
	N	2380	2.3	85	1544	7.7	85
Transplant	Y	178	-1.0	82	73	-9.2	77
	N	2709	3.1	83	2544	9.0	84
BMI	< 25	838	-1.0	80	1022	9.0	82
	25-30	1002	4.3	85	920	9.0	87
	>30	1047	3.5	83	675	6.8	82
<b>Overall</b>		<b>2887</b>	<b>3.0</b>	<b>83</b>	<b>2617</b>	<b>8.5</b>	<b>84</b>

# Interpretation of CKD Testing

Marker of Kidney Damage	GFR	CKD	What to do?
+	< 60	Y	Action Plan
+	$\geq$ 60	Y	Action Plan
-	< 60	Y	Action Plan*
-	$\geq$ 60	N	

Because of bias in MDRD Study equation in non-CKD populations, some individuals with normal measured GFR may have GFR estimates just below 60. Individual decision-making is required.

# Classifications of CKD

- **Severity (stage)**
- **Treatment (HD vs. PD)**
- **Diagnosis (cause)**
- **Prognosis (progression, CVD)**

# Stages of CKD, Related ICD 9 Codes and Classification by Treatment

Stage	Description	GFR (mL/min per 1.73 m <sup>2</sup> )	ICD 9 Code	Treatment
	At increased risk	>60 (with CKD risk factors)		None
1	Kidney damage with normal or ↑ GFR	≥90	585.1	
2	Kidney damage with mild ↓ GFR	60–89	585.2	
3	Moderate ↓ GFR	30–59	585.3	T if kidney transplant recipient
4	Severe ↓ GFR	15–29	585.4	
5	Kidney failure	<15 (or dialysis)	585.5 585.6 (if ESRD) V codes for dialysis or transplantation	D if dialysis (HD or PD)


# Simplified Classification of CKD by Diagnosis

<b>Disease</b>	<b>Major Types (Examples)</b>
<b>Diabetic kidney disease</b>	<i>Type 1 and type 2 diabetes</i>
<b>Nondiabetic kidney diseases</b>	<i>Glomerular diseases</i> <i>(autoimmune diseases, systemic infections, drugs, neoplasia)</i> <i>Vascular diseases</i> <i>(renal artery disease, hypertension, microangiopathy)</i> <i>Tubulointerstitial diseases</i> <i>(urinary tract infection, stones, obstruction, drug toxicity)</i> <i>Cystic diseases</i> <i>(polycystic kidney disease)</i>
<b>Diseases in the transplant</b>	<i>Acute rejection</i> <i>Allograft nephropathy (chronic rejection, calcineurin toxicity, glomerulopathy)</i> <i>Recurrent diseases (glomerular diseases)</i>

# Proposed Classification using ICD Codes

Disease		CKD Classification		
		Stage and Treatment	Marker of Kidney Damage	Disease (ICD Code)
<b>Diabetic Kidney Disease</b>	Type 1	585.X	Proteinuria	
	Type 2	(585.6 For ESRD)	Proteinuria	
<b>Non-Diabetic Kidney Disease</b>	Glomerular diseases	With V codes for D or T	Hematuria ±Proteinuria	
	Vascular diseases		±Proteinuria	
	Tubulointersitial diseases		+Pyuria, ±Proteinuria, ±Imaging studies	
	Cystic diseases		Cysts	
	Non-diabetic kidney disease not otherwise specified		±Proteinuria	
<b>Transplant</b>			±Proteinuria	

# Conceptual Model for CKD




# CKD Risk Factors

Risk Factor	Definition	Examples
Susceptibility factors	Increase susceptibility to kidney damage	Older age, family history of CKD, U.S. racial or ethnic minority status, reduced kidney mass, hyperfiltration states
Initiation factors	Directly initiate kidney damage	Diabetes, high blood pressure, obesity, dyslipidemia, autoimmune diseases, infections, stones, obstruction
Progression factors	Cause worsening kidney damage and faster GFR decline	Higher level of proteinuria
End-stage (outcome) factors	Increase morbidity and mortality in kidney failure	Lower dialysis dose (Kt/V), temporary vascular access, anemia, low serum albumin level, late referral


Factors that are implicated at different stages in the development and progression of CKD are listed in the initial category in which they could potentially appear.





# Conceptual Model for CKD



# CVD Mortality in GP (NCHS) and in Dialysis Patients (USRDS)



# Rates of Death from Any Cause and from CVD by Estimated GFR



## CKD as a Risk Factor for CVD in CVD Risk Factor Conditions

<b>CVD Risk Factor</b>	<b>CKD prevalence</b>	<b>CKD as a risk factor for CVD morbidity</b>	<b>CKD as a risk factor for CVD mortality</b>
<b>Hypertension</b>	↑	↑	↑
<b>Diabetes</b>	↑	↑	↑
<b>Dyslipidemia</b>	↑	↑	↑

# Rationale for Public Health Policy

- CVD is most common cause of death in developed nations
- CKD is common in people with CVD risk factors
  - Hypertension, diabetes, dyslipidemia
- CKD multiplies risk for CVD
- Patients with CVD risk factors and CKD are more ill compared to those without CKD
  - Risk factor levels are higher
  - Risk factor control is more difficult
  - CVD outcomes are worse
  - Costs of care are higher
- CVD risk factor management differs in patients with CKD compared to those without CKD
- Treatments are available and effective NOW
  - To reduce CVD risk
  - To manage complications of CKD
  - To slow kidney disease progression

# Chronic Kidney Disease is a Public Health Problem

- CKD is common
  - 11% of US adults
  - Higher prevalence in patients with CVD risk factors
- CKD is harmful
  - Increased risk for CVD
  - Complications of decreased kidney function
  - Progression to kidney failure
- We have treatment

# Recommendations

- CKD testing for all patients with CVD risk factor conditions
- CKD Action Plan for all patients found to have CKD

# CKD as a Risk Factor for Adverse Outcomes of Infectious Diseases

<b>Infectious Disease</b>	<b>CKD prevalence</b>	<b>CKD as a risk factor for ID morbidity</b>	<b>CKD as a risk factor for ID mortality</b>
<b>HCV</b>			
<b>HBV</b>			
<b>HIV</b>			
<b>TB</b>			
<b>Malaria</b>			



## CKD as a Risk Factor for Adverse Outcomes of Cancer

<b>Cancer</b>	<b>CKD prevalence</b>	<b>CKD as a risk factor for cancer morbidity</b>	<b>CKD as a risk factor for cancer mortality</b>
<b>Kidney and urinary tract tumors</b>			
<b>Other solid tumors</b>			
<b>Hematologic malignancies</b>			

<b>CKD Concepts</b>	<b>Where We Are Now</b>	<b>Where We Need to Go</b>
<b>Conceptual Model</b>	Well developed	Link to AKI and AKD
<b>Definition</b>	Inclusive	Markers of damage
<b>Testing</b>	Spot urine albumin-to-creatinine ratio >30 mg/g; eGFR <60 ml/min/1.73 m <sup>2</sup>	Standardization Race/ethnicity terms Optimal use
<b>Prevalence</b>	US	World
<b>Classification</b>	Severity (ICD9) Treatment	Link to ICD I0-11 Diagnosis, Prognosis
<b>Risk Factors</b>	Framework	Focus on CVD risk factors
<b>Outcomes</b>	CVD	ID, cancer
<b>Public Policy</b>		Simple messages Coordinate with other chronic diseases

# CKD as a Global Public Health Problem

---

